# The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.

> **NCT06601010** · — · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06601010
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-24
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06601010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06601010, "The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06601010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*